ClinicoEconomics and Outcomes Research最新文献

{"title":"What to Expect in 2026-2027: Important Health Economics and Outcomes Research Topics.","authors":"Ivo Abraham, Mickael Hiligsmann, Kenneth K C Lee, Giorgio L Colombo, Leslie Citrome, Mike Gregg","doi":"10.2147/CEOR.S594790","DOIUrl":"10.2147/CEOR.S594790","url":null,"abstract":"<p><p>An infographic titled 'What to Expect in 2026-2027: Important Health Economics and Outcomes Research (HEOR) Topics' outlines five key HEOR areas. 1. HEOR Models: AI is transforming HEOR with advanced data, but needs validation to avoid errors. 2. Real World Evidence: Essential in healthcare, it connects clinical trials with real-life practice for improved access and regulation. 3. Prevention Economics: Now a policy focus, showing that investing in prevention is financially crucial for effective implementation. 4. Health Equity: Involves expanding access, integrating social determinants and developing methods to measure healthcare impact. 5. Healthcare Resource Reallocation: Spending is shifting from austerity to resilience, emphasizing prevention for better fiscal outcomes than defense spending. The infographic includes decorative elements.An infographic listing top five HEOR topics for 2026-2027, numbered 1 to 5 with headings and summaries.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"594790"},"PeriodicalIF":2.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13505552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Fetal Fibronectin Testing in Women at Risk for Preterm Birth: A Retrospective Cohort Study.","authors":"Dina Abushanab, Nader Al-Dewik, Reem AlNasr, Reem Alenany, Lana Kattan, Ghaith Alali, Alaa Al-Naama, Moza Al-Hail, Thomas Farrell, Haseebur Rahman Khan Mohammed, Wessam Elkassem, Abdulrouf Pallivalapila, Binny Thomas, Daoud Al-Badriyeh","doi":"10.2147/CEOR.S611886","DOIUrl":"https://doi.org/10.2147/CEOR.S611886","url":null,"abstract":"<p><strong>Introduction: </strong>The fetal fibronectin (fFN) test is used to predict true preterm delivery. This study aims to evaluate the cost-effectiveness of fFN testing versus no-fFN testing in identifying true preterm labor among women with preterm labor symptoms at risk for premature birth.</p><p><strong>Methods: </strong>This retrospective cohort-based study was conducted among women who presented with symptoms of preterm labor between 24 and 34 weeks of gestation at a tertiary care hospital in Qatar and compared outcomes between those who received fetal fibronectin (fFN) testing and those who did not. A decision-tree model compared fFN testing to no testing, with the primary outcome being the incremental cost-effectiveness ratio, representing the additional cost for a successful delivery within 48 hours of admission. Clinical data were collected from HMC medical records, and direct medical costs was locally obtained, reflecting the Qatari hospital perspective. Sensitivity analyses confirmed the study results.</p><p><strong>Results: </strong>A total of 519 women were analyzed. Significant baseline differences were observed between groups. The proportion of delivery within 48 hours was higher in the fFN group (94% vs 80%, P<0.0001). fFN testing was associated with a cost saving of QAR6,470 (US$1,777) per successful delivery.</p><p><strong>Conclusion: </strong>fFN testing was associated with better short-term clinical outcomes and lower healthcare costs. Nonetheless, due to the retrospective observational nature of the study and differences in baseline characteristics between groups, these results should be interpreted cautiously.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"611886"},"PeriodicalIF":2.6,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13468297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition from Free to Paid Vaccination: Willingness to Pay for COVID-19 Booster Doses in Vietnam in the Post-Pandemic Era.","authors":"Thanh Van Nguyen, Cuong Tat Nguyen, Trang Huyen Bui, Van Anh Thi Pham, Xuan Thi Thanh Le","doi":"10.2147/CEOR.S615279","DOIUrl":"10.2147/CEOR.S615279","url":null,"abstract":"<p><strong>Objective: </strong>As COVID-19 transitions to an endemic stage, low- and middle-income countries face fiscal challenges in sustaining fully subsidized vaccination programs. This study aims to estimate the willingness to pay (WTP) for COVID-19 booster doses and identify determinants of demand among Vietnamese adults during the transition to a user-fee mechanism.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted in 2024 in Thanh Hoa Province, Vietnam, involving 405 adult participants recruited through convenience sampling from a single hospital setting. Data were collected through direct interviews using a structured questionnaire. The Contingent Valuation Method utilizing a double-bounded dichotomous choice format was employed to elicit WTP. Multivariable logistic regression was applied to determine factors associated with willingness to pay, while linear regression analysis was applied to examine determinants of the payment amount.</p><p><strong>Results: </strong>Among 405 participants, the estimated mean WTP for a COVID-19 booster dose was VND 410,046 (approx. US$ 15.7), whereas the median WTP was significantly lower at VND 201,307 (approx. US$ 7.7), indicating a right-skewed distribution. Multivariable logistic regression showed that married participants and those in higher income groups were more likely to report willingness to pay, whereas poor self-rated health and prior adverse events following vaccination were associated with lower willingness to pay. Linear regression analysis indicated that female participants and older individuals reported lower payment amounts, while those with a prior history of COVID-19 infection reported higher payment amounts. Notably, the median WTP was substantially lower than the estimated market price of imported mRNA vaccines, indicating a potential affordability gap between stated valuation and prevailing market prices for COVID-19 booster vaccination.</p><p><strong>Conclusion: </strong>These findings emphasize the necessity of flexible financing approaches to maintain vaccine uptake and prevent widening disparities during the transition to paid vaccination. As the study was conducted using convenience sampling at a single hospital, the findings should be interpreted with consideration of limited generalizability.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"615279"},"PeriodicalIF":2.6,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.","authors":"Jennifer E Vaughn, Nadine Zawadzki, Shurui Zhang, Paul Pinkston, David Wei, Jason Shafrin","doi":"10.2147/CEOR.S626752","DOIUrl":"10.2147/CEOR.S626752","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the financial impact of treating CML with later-generation TKIs relative to imatinib on US patients and payers.</p><p><strong>Methods: </strong>The financial impact of later-generation TKIs (asciminib, bosutinib, dasatinib, nilotinib, and ponatinib) and imatinib was measured from patients' and payers' perspectives before (2024) and after the implementation of Inflation Reduction Act (2025), respectively. Changes in patient's annual out-of-pocket (OOP) costs of CML therapies by payer type (Medicare, Medicaid, and commercial) were used to indicate the financial impact on patients. Per patient per year (PPPY) treatment costs were measured as the weighted average cost across indicated adult CML populations derived using FDA label-based dosing and wholesale acquisition costs. Annual OOP limits by payer types were determined through literature review. The financial impact from payers' perspective was estimated as difference in monthly premium based on per member per month (PMPM) budget impact.</p><p><strong>Results: </strong>In 2025, the estimated PPPY cost for imatinib ($22,430 across generic and branded products, weighted by market share) and for later-generation TKIs (all >$100,000 except for dasatinib and nilotinib, which were $72,693 and $89,138, respectively) exceeded annual OOP limits under Medicare Part D, the average commercial plan, and the commercial plan with highest possible annual OOP limit, resulting in no change in patient financial impact when switching from imatinib to a later-generation TKI. An all-payer blended US health plan with 1 million members could expect to have 200 patients with Philadelphia chromosome-positive CML eligible for TKI therapy. Switching from imatinib to a later-generation TKI would increase the PMPM budget impact between $0.76 and $4.23.</p><p><strong>Conclusion: </strong>Both imatinib and later-generation TKI costs were projected to exceed annual OOP caps in 2025, likely resulting in minimal change in insured CML patients' OOP costs. The impact on insurance premiums from the adoption of TKI is likely to be relatively modest.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"626752"},"PeriodicalIF":2.6,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13357042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Automated Blood Culture Systems: Comparison of BACT/ALERT VIRTUO and BD BACTEC FX from a Provider Perspective.","authors":"Pallavi Krishnamurthy, Pablo Anaya, S Pinar Bilir, Kristen L Jurcic Smith, Amanda L Suchanek, Hari P Dwivedi, Shawn H MacVane","doi":"10.2147/CEOR.S560812","DOIUrl":"10.2147/CEOR.S560812","url":null,"abstract":"<p><strong>Background: </strong>The BACT/ALERT® VIRTUO® system (VIRTUO system) and BD BACTEC™ FX (FX system) can rapidly detect microbial growth in patients with bloodstream infections (BSIs). The cost-effectiveness model presented in this study compared the estimated economic and clinical consequences of adopting these systems.</p><p><strong>Methods: </strong>A decision tree framework with a one-year time horizon, for a hypothetical population of 10,044 patients was developed to estimate differences in clinical and economic outcomes between the VIRTUO and FX systems. Outcomes included hospital-based mortality, hospital length of stay (LOS) and costs, and total costs (USD, $) for 2023. One-way sensitivity (OWSA) and scenario analyses were performed to evaluate the robustness of the model.</p><p><strong>Results: </strong>From a US provider's perspective, the base case showed a reduction in mortality rate (VIRTUO system: 18.03%; FX system: 19.67%) and cumulative hospital LOS (VIRTUO system: 12,804 days; FX system: 12,871 days) for patients with blood cultures tested with the VIRTUO system compared to the FX system. Total cost reduction from a provider perspective, led to estimated cost savings of $216,062 per year with the adoption of the VIRTUO system. In the scenario analysis, when the bottle cost of the VIRTUO system increased or decreased by 50%, the testing costs between the VIRTUO and FX systems differed by 35% from the base case. OWSA showed the positivity rate, proportion of patients receiving empirical treatment and septic shock hospital costs were the most influential variables for the model.</p><p><strong>Conclusion: </strong>Adopting the VIRTUO systems by hospitals has the potential to improve patient-related outcomes and economic savings.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"560812"},"PeriodicalIF":2.6,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13356864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Economic Burden Following Percutaneous Coronary Intervention for STEMI: A US Real-World Evidence Study.","authors":"Shanthi Krishnaswami, Brendan Clark, Manu Tyagi, Meenal Sinha, Bonnie M K Donato, Villum Wittrup-Jensen, Zhun Cao","doi":"10.2147/CEOR.S605902","DOIUrl":"10.2147/CEOR.S605902","url":null,"abstract":"<p><strong>Introduction: </strong>ST-segment-elevation myocardial infarction (STEMI) affects approximately 250,000 people in the U.S. annually, causing substantial morbidity and mortality. One-year outcomes following percutaneous coronary intervention (PCI) for STEMI vary across studies.</p><p><strong>Aim: </strong>To assess clinical and economic outcomes following PCI among patients with STEMI.</p><p><strong>Methods: </strong>This study analyzed adult patients with STEMI undergoing PCI between 2016 and 2021, using Premier Healthcare Database and additional mortality and claims data. Clinical outcomes, healthcare resource use, and costs following first PCI discharge (index visit) were assessed for at least 1 year, with outcomes at 3-year follow-up assessed among a subset of patients. Multivariable regression (Cox, logistic or generalized linear) was used to identify risk factors for key outcomes.</p><p><strong>Results: </strong>A total of 180,691 patients underwent PCI for STEMI in 633 US hospitals during the study period. The median age was 62 years, most were male (71%), non-Hispanic White (62.7%), and had Medicare as the primary payor (42.9%). At index visit, 13.8% had ventricular tachycardia, 8.8% had ventricular fibrillation, with a median cost of $17,582, and a mortality rate of 5.5%. Within 1 year, there were 1,966 (1.1%) additional deaths, 17.4% were readmitted, 13.4% developed heart failure (HF), 2.5% were hospitalized primarily for HF (HHF), 3.9% had atrial fibrillation, and 1% experienced recurrent STEMI. The median total study cost by 1 year was $21,010. A Charlson Comorbidity Index (CCI) score of ≥4 (vs <4) at index visit was most strongly associated with higher risk of death at 1 year: hazard ratio: 4.1, (95% CI: 3.66 to 4.49), higher odds of readmissions (OR: 2.6, 95% CI: 2.50 to 2.70), HHF (OR: 4.1 (95% CI: 3.83 to 4.42)), and 74% higher costs (p<0.05). Similar associations were observed at 3-year follow-up (n=59,714).</p><p><strong>Conclusion: </strong>This study identified risk factors associated with one-year negative clinical outcomes and increased cost following PCI for the treatment of STEMI.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"605902"},"PeriodicalIF":2.6,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148354098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Claim Costs of Facioscapulohumeral Muscular Dystrophy in the United States.","authors":"Amanda A Hill, June Kinoshita, Mariefel Nicole Deypalan, Marina Kolocha, Man Hung, Eric Hon, William Sarraille, Wayne Winegarden, Tanyatorn Ghanjanasak, Jamshid Arjomand","doi":"10.2147/CEOR.S576729","DOIUrl":"10.2147/CEOR.S576729","url":null,"abstract":"<p><strong>Purpose: </strong>Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive genetic disorder characterized by asymmetric muscle weakness and functional decline. Although it is one of the most common muscular dystrophies, its economic burden in the United States (US) is largely unknown. This study aimed to provide an initial, conservative estimate of annual medical claims costs and identify comorbidities disproportionately affecting individuals with FSHD in the US.</p><p><strong>Patients and methods: </strong>This retrospective, 1:5 matched case-control study analyzed de-identified claims data from Medicare and commercially insured enrollees from 2018 to 2021. Medical and prescription costs were aggregated and described as means with 95% confidence intervals. <i>T</i>-tests with Bonferroni correction and chi-square tests were used to compare comorbidity prevalence.</p><p><strong>Results: </strong>The study included 383 individuals with FSHD and 1915 matched controls. The mean annual medical claims cost for the FSHD cohort was $19,370 per person with commercial insurance and $11,704 with Medicare, compared with $5250 among controls. Individuals with FSHD also incurred higher prescription claims costs in commercial and Medicare subgroups without comorbidities. The prevalence of cerebrovascular disease (10.18% vs 4.44%) and ear disorders (8.09% vs. 3.39%) was significantly greater in the FSHD cohort (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>This exploratory study provides the first US-based description of the direct medical costs of FSHD, demonstrating a substantially higher healthcare burden than that of matched controls. Because the study design likely underestimates costs, the true economic impact may be even greater. These findings establish a critical foundation for future research into the lifetime medical, nonmedical, and caregiver-related costs of FSHD, and highlight the urgent need for effective therapies and supportive care strategies.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"576729"},"PeriodicalIF":2.6,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs.","authors":"Valentina Perrone, Vanessa Innao, Stefania Mazzoni, Maria Cappuccilli, Margherita Andretta, Fausto Bartolini, Alessandro Chinellato, Stefania Dell'Orco, Fulvio Ferrante, Renato Lombardi, Romina Pagliaro, Loredana Ubertazzo, Paola Valpondi, Luca Degli Esposti","doi":"10.2147/CEOR.S598572","DOIUrl":"10.2147/CEOR.S598572","url":null,"abstract":"<p><strong>Background: </strong>Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, mainly affecting older people. Targeted agents have reshaped first-line (1L) strategies, making real-world evidence important to complement clinical trials.</p><p><strong>Objective: </strong>To estimate the incidence of Italian patients initiating first-line CLL therapy (2019-2022) and describe demographics/clinical profile, treatment patterns, adherence, outcomes (overall survival [OS], time to next treatment [TTNT]), and healthcare costs from the perspective of the Italian National Health System (NHS).</p><p><strong>Methods: </strong>A retrospective observational study using administrative healthcare databases (~9 million residents) was conducted on CLL patients starting 1L therapy (index-date) for CLL. Baseline characteristics were assessed in the 12 months pre-index; follow-up was ≥12 months. Drug use, adherence (medication possession ratio), dose adjustments, OS, TTNT, and direct costs were analyzed with descriptive and multivariable methods.</p><p><strong>Results: </strong>A total of 1479 patients initiated 1L therapy: 63.9% chemotherapy (CHT), 23.2% ibrutinib, 3.2% acalabrutinib, and 9.7% other regimens. CHT remained common, especially among older and more comorbid patients. Ibrutinib showed lower mortality versus CHT (HR 0.663; p=0.002) and longer TTNT (median not reached). Dose adjustments were frequent; extended refill intervals did not appear to reduce drug survival. Mean annual cost per patient was €38,573, mainly driven by drug acquisition; ibrutinib users had lower hospitalization and outpatient costs than other 1L groups.</p><p><strong>Conclusion: </strong>In Italian practice, ibrutinib was the main targeted 1L option and was associated with improved survival and delayed progression versus CHT. Despite higher drug costs, reduced hospital-based resource use suggests favourable overall clinical and economic impact.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"598572"},"PeriodicalIF":2.6,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total Laboratory Automation for Microbiology Activities: An HTA Analysis in an Italian Laboratory Setting.","authors":"Emanuela Foglia, Elisabetta Garagiola, Lucrezia Ferrario, Edmondo Adorisio, Giuseppe Gagliardi, Francesca Domenica Lenoci","doi":"10.2147/CEOR.S597703","DOIUrl":"10.2147/CEOR.S597703","url":null,"abstract":"<p><strong>Objective: </strong>Microbiology laboratories face increasing challenges related to rising sample volumes, workforce constraints, and the need for improved diagnostic accuracy and efficiency. Total Laboratory Automation (TLA) has emerged as a transformative solution to optimize workflows, enhance safety, and improve resource utilization. This study focuses on urine cultures and the follow-up of positive blood cultures and evaluates the impact of TLA implementation in a microbiology laboratory, assessing efficiency, economic sustainability, and healthcare professionals' perceptions.</p><p><strong>Methods: </strong>A Health Technology Assessment (HTA) approach was employed, integrating real-life data from a single-center hospital laboratory in Italy before and after TLA implementation. Key performance indicators (KPIs) were defined through a literature review and expert consensus. Real-life data were collected over two time periods: the pre-automation phase (manual workflow) and post-automation phase (TLA) for urine culture and positive blood culture. The economic and organizational impact was assessed by quantifying human resource efforts, while a qualitative survey captured healthcare professionals' perceptions regarding automation.</p><p><strong>Results: </strong>TLA significantly reduced sample processing times, with a 67% decrease in check-in time and a significant reduction in inoculation (up to 100%) and plate reading (-69%) times, respectively. Economic analysis indicated a 67% reduction in costs for personnel time required to process urine cultures and perform initial workups of positive blood cultures on annual basis with consequent organizational benefits, in terms of time spent in sample processing (-71%). Healthcare professionals reported improved safety and reduced workload, making them more inclined to adopt TLA, perceived as useful and capable to offer high-quality and demonstrable results.</p><p><strong>Conclusion: </strong>Findings emphasize TLA potentialities in the management of microbiology procedures overall improvement, empowering the laboratory efficiency and organizational capacity, allowing better investment of the human resources involved.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"597703"},"PeriodicalIF":2.6,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13281764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy.","authors":"Gianni Ghetti, Luca Castello, Linet Awino Odonde, Serena De Fazio, Andrea Stella, Angela Bruno, Emanuele Marchionne, Massimiliano Bonifacio","doi":"10.2147/CEOR.S599644","DOIUrl":"10.2147/CEOR.S599644","url":null,"abstract":"<p><strong>Background: </strong>While chemotherapy is the standard treatment for adults with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL), long-term remission remains difficult to achieve. Blinatumomab, an immunotherapy drug, has shown survival benefits when alternated with consolidation chemotherapy in patients with CD19-positive Ph- B-cell ALL, but its economic value had not been assessed in Italy.</p><p><strong>Methods: </strong>This study evaluated the cost-effectiveness of alternating blinatumomab with standard consolidation chemotherapy compared with chemotherapy alone, using data from the ECOG-ACRIN E1910 Phase III trial. A model was developed to estimate lifetime health outcomes and costs from the perspective of the Italian National Health Service.</p><p><strong>Results: </strong>Patients who received blinatumomab lived on average 5.06 years longer and gained 4.56 more quality-adjusted life years, but incurred higher healthcare costs, with an incremental cost of €165,401 per patient, primarily due to drug acquisition. The incremental cost-effectiveness ratio (ICER) was €36,261 per quality-adjusted life year gained, within the range of values typically considered acceptable in Italy. These results were confirmed in sensitivity analyses, with the ICER ranging from €28,082 to €49,034 under various assumptions.</p><p><strong>Conclusion: </strong>The alternation of blinatumomab with chemotherapy provides a substantial clinical benefit at a cost that is likely acceptable to the Italian healthcare system. These findings support the value of blinatumomab in improving outcomes in adult patients newly diagnosed with Ph- CD19-positive B-cell ALL. Results were consistent across sensitivity analyses, supporting the robustness of the findings.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"599644"},"PeriodicalIF":2.6,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}